Dossier assessment
Mepolizumab (asthma) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Mepolizumab (asthma) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Mepolizumab (asthma) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Add-on treatment for severe refractory eosinophilic asthma in adolescents and children aged 6 years and older
Added benefit not proven due to lack of suitable data
Additional information
Federal Joint Committee (G-BA)
2019-03-22 A G-BA decision was published.
Project details
- Project no.
- A18-58
- Commission
- Commission awarded on 24.09.2018 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Airways and respiratory system, Children's and adolescents' health
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Mepolizumab - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Mepolizumab (COPD) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Mepolizumab (eosinophilic granulomatosis with polyangiitis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Mepolizumab (hypereosinophilic syndrome) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Mepolizumab (chronic rhinosinusitis with nasal polyposis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed